BreakoutScan — the stock scanner that explains itself

The stock scanner that explains itself

5,500 stocks move every morning.

Gappers, 8‑Ks, PRs, S‑3s — more than any small‑cap trader can read before the bell.

Almost all of it is noise.

A screener shows you what moved. It won't tell you why, what's still pending, or who has an ATM on file.

We find the few that matter — and tell you why.

Stop hunting for the next catalyst. We read the night's filings and releases, so you start the day with a short list and the catalysts still ahead.

Start your 7-day free trial See how it works

No charge for 7 days. Cancel any time before then.

Sample dataSample data · the tickers are fictional

Built for the small-cap morning

The questions behind every trade, answered in one window.

“Before BreakoutScan my morning routine was basically TradingView, SEC filings, news feeds, screeners and way too many browser tabs.”

Marcus T.

Market open · 9:58 AM ET

Catalysts

Pending · sorted by timeline

Pending only

AXVLShareholder vote on the mergerDealOct 28

HLXRPDUFA date for HX-201FDA decisionNov 9

PDUFA date for HX-201Nov 9 · in 47 days

Source: 8-K filed Aug 13, 2026 · 10-Q filed Aug 13, 2026Open the filing

ORRAPhase 2 topline dataTrial readoutDec 3

VNTAFirst production at Sable fieldLaunchQ4 2026

PLNXProduction award decisionContractQ1 2027

KALOPhase 2 topline dataTrial readoutQ2 2027

Sample data — the tickers are fictional.

5,500+
US stocks scanned every session
4,500+
companies with catalyst analysis¹
Nightly
new filings read and analyzed²
1,850+
traders in our private beta³

7:00 AMThe read

By 7:00 AM it's read, rated and explained.

Overnight, BreakoutScan reads the new filings and releases for every stock it covers, and turns the one sentence that matters into a card you can act on.

01Read

Form 8-K · Helixar Therapeutics · Item 8.01Filed Aug 13, 2026

On August 13, 2026, the Company announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for HX-201 for the treatment of moderate plaque psoriasis. The FDA has assigned a Prescription Drug User Fee Act target action date of November 9, 2026. The FDA has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application. The Company had cash and cash equivalents of $61.0 million as of June 30, 2026.

The filing itself, not a summary of a summary. The sentence that matters is found and kept in the company's own words.

02Rated

FDA decisionImpact · High

PDUFA date for HX-201

Magnitude — a binary FDA decision on the lead program
Concreteness — dated by the FDA; no advisory committee
Cap leverage — a $96M company against a $1B+ market

Rated by what the event could move, weighed against the company's size — never by timing, never by hype.

03Explained

HLXR

Helixar Therapeutics

Nov 9 · in 47 days

The FDA decides on HX-201 by November 9, with no advisory committee planned — and the cash on hand reaches past the date.

Source: 8-K · Aug 13, 2026Open the filing

One line a trader can read at a glance, with the filing it came from a click away.

HKCS-1.0%HLXR+38.4%CSD+9.5%KALO+21.7%THKK+5.8%QRKS+17.9%QKMR+6.9%DSTB+6.4%DPCK-0.1%VSZ+8.5%KTBG-1.7%FHW-0.8%XSF-1.0%PPLH+10.3%MBTD+4.6%RLPH+10.1%DFB+2.8%HJSN+5.1%NFQK-4.5%CRZB-2.6%KTJJ+7.0%PSV-4.3%QKFK+0.8%MZQ+4.1%

VNTA+12.2%GQM+8.8%TRNW-18.6%RJGN+8.4%MRDH-9.4%MQXQ+0.2%CTSS+1.7%LKCB-3.8%CPXL+0.8%XLXT+8.7%FRMK+10.0%JNNL-4.4%PHMM+1.1%RSTT+3.3%CSQP-0.1%RCVD+10.4%ZVC+3.2%VGL+1.2%ZDNF+2.2%WPCT-4.8%BZND-4.5%BFPF+8.0%HJDR+2.5%MFJR+9.2%

9:30 AMThe open

The bell rings. The reason, the risk, what's running — and the level.

Catalysts

Know what's coming, and when.

PDUFA dates, topline readouts, contract awards, deal closings. The events small caps trade on are buried in 8‑Ks, 10‑Qs and press releases. We pull out the ones the company has put on the record, dated in its own words, with the source attached.

Pending events first: FDA decisions, readouts, deals, launches
Dated only when the company dates it, “No date” when it doesn't
Linked to the filing or release it came from

HLXRBiotech · $96M cap

Helixar Therapeutics

$4.86

+38.4%

Primary catalyst

FDA decisionImpact · HighNov 9 · in 47 days

PDUFA date for HX-201

The FDA's decision on HX-201 for moderate plaque psoriasis is expected by November 9, 2026; the review is on schedule and no advisory committee is planned.

8-K filed Aug 13, 202610-Q filed Aug 13, 2026

Open the filing

Also pendingin timeline order

ORRATrial readoutPhase 2 topline dataDec 3
VNTALaunchFirst production at Sable fieldQ4 2026
KALOTrial readoutPhase 2 topline data4 months of cashQ2 2027

Dilution and cash runway

A perfect chart. Then the offering.

Small caps pay for their catalysts by selling stock. BreakoutScan puts each company's cash runway beside its catalyst, with the shelf, the ATM and the warrants on file, so you can see who's funded to get there and who may have to raise first.

Cash and burn from the latest 10-Q, dated
Shelf registrations, ATMs and warrants on file
A raise-likely flag before the event, not after

“A chart can look perfect, but if the company has an ATM or a ton of warrants sitting there, I want to know before I touch it.”

Priya S.

Stock	Catalyst	Cash runway	Status
HLXR Helixar Therapeutics	PDUFA date for HX-201 Nov 9 · in 47 days	19 mo No ATM active	Funded
QRKS Quarkspin Systems	Defence supply agreement Completed · Sep 23	31 mo	Funded
VNTA Ventara Energy	First production at Sable field Q4 2026	4 mo ATM active · $18M left	Tight
KALO Kalo Bio	Phase 2 topline data Q2 2027	4 mo ATM active · $12M left	Raise likely

Months of cash at the current burn · bars run to 30 monthsthe catalyst's date

See the dilution read on the stocks you trade, free for 7 days

Runners

What's running, and the news behind it.

The day's top gainers and losers, pre-market to after hours, on one chart — with the release, the filing or a one-line read of the move beside each one. On the Runners list, a mover's float, short interest and any ATM, shelf or warrants on file sit on the same row.

Pre-market to after hours, live
The top gainers and losers as lines you can zoom into
Order flow on the names you watch

Pattern detection

The trend lines, already drawn.

Every night we draw the trend lines on 5,500+ charts and mark the level that matters, so you see how far each stock sits from it, and when it breaks through.

Triangles, flags, wedges and ranges, detected automatically
Distance to the level on every stock, redrawn every night
The volume profile, drawn and screened the same way

Ascending triangle

15.7% above the level

Helixar Therapeutics

$4.86

+38.4%

The assistant

Ask it what you would ask an analyst.

It answers from BreakoutScan's own data first — exact counts, the filings behind them — and says so when it doesn't know. Never advice; your decision.

Which biotechs under $100M have a readout or FDA decision dated before year end and more than a year of cash? (start a free trial to ask it)
Two names match. Not advice — your decision.HLXRORRA
Why is HLXR up today? (start a free trial to ask it)
Show me stocks within 2% of their level with a catalyst (start a free trial to ask it)

4:00 PMThe close

Tested by 1,850 traders for a month before it was priced.

A month-long private beta with active US small‑cap traders shaped what shipped. These are their words.

With BreakoutScan I can see upcoming catalysts, recent news and the setup in one place. I spend way less time researching random tickers and more time focused on trades that actually fit my criteria.

Daniel K.

The dilution data is probably what I use the most. A chart can look perfect, but if the company has an ATM or a ton of warrants sitting there, I want to know before I touch it.

Priya S.

Before BreakoutScan my morning routine was basically TradingView, SEC filings, news feeds, screeners and way too many browser tabs. Now I can see what’s moving, the catalyst behind it, dilution risk, float, short interest and the chart setup without piecing everything together myself. And I’ve finally found consistency in my strategy.

Marcus T.

Catalysts link to the filing or release they came from.

Read straight from SEC EDGAR, GlobeNewswire and the wires — 6 sources, every weeknight.

Estimates are labelled as estimates. Nothing here is advice.

One plan, everything included.

Try it free for 7 days. Cancel before the trial ends and you won't be charged.

MonthlyBilled monthlyCancel any time.AnnualFounders’ Rate$708 billed yearlysave 60%A founders’ rate we won’t always offer.

Start 7-day free trial

Reminder before day 7
Cancel from your account

“BreakoutScan just made it much easier to find stocks with near-term catalysts and minimal dilution. The two things I was always digging through multiple sites to figure out.”

KenFull-time swing trader

Everything in BreakoutScan Pro

Every feature, whichever way you pay.

Live runners from pre-market to after hours
Pattern and level detection on 5,500+ stocks
Catalyst board with dilution and cash runway
Order flow on your watchlists
The volume-profile scanner
The BreakoutScan assistant

Questions

What's included in the free trial?

The full product, every feature and every stock we cover, for 7 days. Nothing is charged today. You add a card at sign-up; if you don't cancel before the trial ends, it's charged automatically at the plan price you picked. The card also keeps free trials to one per person. If you've had a trial before, sign-up tells you so and shows the price before anything is charged. The one difference is the AI assistant: 150 credits during the trial, 1,200 a month for members.

What happens when the trial ends?

About two days before it ends (around day 5), we email you the date and your plan's price. When the 7 days are up, your plan starts at the price you picked, unless you've cancelled. Cancel before then and you pay nothing.

How do I cancel?

From your account page, any time. No email or phone call needed. Before you confirm, we ask why you're leaving and offer a way to stay (extra days or a discount during the trial; a pause or a discount on a paid plan), and you can say no to each. Cancel during the trial and you're never charged, and access ends right away. Cancel a paid plan and you keep access until the end of the period you've paid for.

Where does the data come from, and how fresh is it?

Catalysts are read from SEC filings (8-K, 10-Q, 10-K, S-1, 424B and more), from releases on the major newswires (GlobeNewswire, PR Newswire, Business Wire, ACCESS Newswire and Newsfile), and from each company's own announcements. Catalysts link to the filing or release they were read from. Each weeknight we check every company we cover for new filings and re-read the ones with something new; chart patterns and trend lines are redrawn nightly too. Prices and runners update live from pre-market to after hours. Order flow refreshes every 10 to 30 minutes through the session.

Where do the float and short-interest numbers come from?

Short interest is a market-data figure, and so is float where one is published; where none is, we estimate it from the company's ownership filings. Both move slowly: the Runners list shows last night's first and a fresher one where there is one. Squeeze Fuel is our own 0 to 100 read of how loaded the short side is, built from figures like short interest, the cost to borrow and how many times the float has traded this session. It's fuel, not a buy signal. Dilution Risk names what a company has on file to sell new shares (an ATM, a shelf, an S-1, warrants) as of our last read of its SEC filings, so a filing made today may not be in it yet. A dash means we don't have that figure.

Who writes the catalyst cards, and what if one is wrong?

An AI model reads each company's recent filings and releases and drafts the card. Rules in code then set its dates and check its impact rating. It can still get one wrong, so cards link to their source, show the day they were analyzed, and say when a newer filing hasn't been read yet. If you spot a mistake, email support@breakoutscan.com with the ticker.

How is this different from a screener or a trading chat room?

A screener filters numbers, and a chat room tells you what someone else thinks. BreakoutScan reads the filings and releases behind every stock it covers, pulls out the pending event (dated in the company's own words when the company gives a date), and puts the cash runway and any shelf, ATM or warrants on file next to it. Catalysts link to their source, so you can check them yourself.

Who is it for, and which stocks does it cover?

Active traders of US small caps who trade around news, catalysts and breakouts. It scans 5,500+ US-listed common stocks and ADRs every session. It doesn't cover OTC stocks, options or crypto, so if that's your market, it isn't the right tool.

Is BreakoutScan financial advice?

No. BreakoutScan is a research tool, not a broker or an investment adviser, and nothing in it is a recommendation to buy or sell. It reads the filings, finds the levels and flags dilution and cash risk. Labels like "high impact" describe how the software sorted the data, not what you should do. The decision is always yours.

What is the Founders' Rate, and will my price go up?

It's the annual plan: $708 a year, which works out to $59 a month, against $1,788 for a year at the $149 monthly price. It's our early-member rate, and we won't always offer it. If prices ever change, you'll get at least 30 days' notice before your next renewal, and you can cancel from your account page before then.

Can I get a refund?

As a rule, no. Except where the law requires it, payments aren't refunded, including for part of a month or year. That's why first-time members get 7 days free and an email before the first charge, so you can decide before you pay anything.

How is order flow calculated?

On most stocks, every trade is marked buyer- or seller-initiated by the tick test (did it print above or below the last different price), and larger orders are checked against the bid and ask at that moment where quote data allows. Companies over $10B, and days with a very heavy tape, use a simpler one-minute money-flow measure. Public data doesn't show who started a trade, so it's an estimate, and we label it as one.

What does the assistant do, and does it cost extra?

Ask in plain words, like "biotechs under $100M with an FDA decision before year end". It answers from BreakoutScan's own data first, with exact counts, and says so when it doesn't know. It's included: 1,200 credits a month (about 240 standard answers; a web search inside an answer adds one credit) and 150 during the trial. It's read-only, and nothing it says is advice.

Do you sell my data?

No. We don't sell your personal information, and we don't use third-party advertising trackers. Stripe handles payments, so your full card number never reaches our servers. The assistant sends your question and the data needed to answer it (such as your watchlist tickers) to an outside AI provider, never your name, email, payment details or account ID. The Privacy Policy names that provider.

Can I use it on my phone?

It runs in your web browser on a computer or a phone, so there's nothing to install; the Desk and the scanners are built for a bigger screen. One browser can be signed in at a time: signing in somewhere else signs the first one out.

Still have a question? support@breakoutscan.com

9:30 AMNext session

The next session opens in

--:--:--

Eastern Time · the next trading session

Tonight's filings are read overnight. By the time you're up, the cards are on the board.

The next session's runnersafter the bell

NMBLFDA clearance for the 510(k)+26.1%

SDRAReverse split effective; float reset+44.0%

CRVNS-1 withdrawn; no offering+19.5%

Be there before the bell See the pricing

7 days free. Cancel any time before then.

5,500 stocks move every morning. Almost all of it is noise. We find the few that matter — and tell you why.

The questions behind every trade, answered in one window.

By 7:00 AM it's read, rated and explained.

The bell rings. The reason, the risk, what's running — and the level.

Know what's coming, and when.

A perfect chart. Then the offering.

What's running, and the news behind it.

The trend lines, already drawn.

Ask it what you would ask an analyst.

Tested by 1,850 traders for a month before it was priced.

One plan, everything included.

Everything in BreakoutScan Pro

Questions

The next session opens in

The questions behind every trade, answered in one window.

By 7:00 AM it's read, rated and explained.

The bell rings. The reason, the risk, what's running — and the level.

Know what's coming, and when.

A perfect chart. Then the offering.

What's running, and the news behind it.

The trend lines, already drawn.

Ask it what you would ask an analyst.

Tested by 1,850 traders for a month before it was priced.

One plan, everything included.

Everything in BreakoutScan Pro

Questions

The next session opens in